Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials

By In The News
March 16, 2019 in The Headlines

Recommended Posts

In The News

Posted March 16, 2019

- Share

Posted March 16, 2019

RALEIGH, N.C. and SHANGHAI, March 16, 2019 /PRNewswire/ -- Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp. (Nasdaq: BCAC), today jointly announced that China, Spain and Poland authorities have approved Xynomic's application...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219840
2. Jaydee
  16730
3. Kip Powick
  12210
4. deicer
  12196
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270.1k
- Total Posts
  
  558.6k

Sign In

Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support